Humana Faces Rating Challenges, Yet TD Cowen Stays Positive
Humana's Recent Challenges and TD Cowen's Outlook
Recently, TD Cowen has reaffirmed its Buy rating on Humana (NYSE: HUM) while keeping a steady price target at $402.00. The firm is addressing the recent reveal from Humana that only 25% of its members will hold plans rated 4 Stars and above in the upcoming year, a drastic decline from 94% recorded in 2024. This significant change is particularly noticeable in contract H5216, where approximately 45% of its members will see their ratings drop from 4.5 to 3.5 stars.
Impact of Star Ratings on Premiums
The change in star ratings is anticipated to have a considerable effect on Humana's premiums in 2026. The company contends that the decrease is due to narrowly missing higher industry benchmarks on various measures, and they are in the process of contesting some of these results. Star ratings play a critical role as plans rated 4.0 stars or higher receive a 5% quality bonus adjustment to benchmark rates, while those rated 4.5 stars or above enjoy a more favorable 70% rebate compared to a 65% rebate for ratings between 3.5 and 4.0 stars.
Financial Predictions and Future Considerations
The potential financial impact from these changes on Humana's earnings per share (EPS) and profit margins is contingent upon multiple factors. This includes how well Humana can counteract premium losses by adjusting benefits, the total Medicare Advantage rate for 2026, the version 28 (v28) impact, and the rising cost trends for the upcoming year. Additionally, the enrollment dynamics will also play a role in how these changes affect Humana's financial landscape.
Leeway with CMSS
Plans that are experiencing lower star ratings might find more flexibility with the Centers for Medicare & Medicaid Services (CMS) total beneficiary cost reduction limits. It could enable them to maintain margins if they opt to exercise this choice, which could be a strategic move for Humana moving forward.
Market Reactions and Analyst Ratings
Humana is currently encountering obstacles due to its considerable decline in Medicare Advantage Star Ratings for the upcoming year. The company’s contract H5216, which encompasses a large segment of its Medicare Advantage membership, experienced a ratings drop from 4.5 stars to 3.5 stars. As a result, the proportion of members enrolled in 4-star and above plans fell sharply in 2025. Despite these setbacks, Barclays still holds an Overweight rating and a price target of $364.00 on Humana.
Competitors’ Perspectives
In contrast, Morgan Stanley and JPMorgan have upheld their Equal-weight and Neutral ratings toward Humana. However, the position taken by Leerink Partners has shifted, downgrading Humana's stock from Outperform to Market Perform due to apprehensions regarding the company's performance outlook linked to decreasing star ratings.
Evolent Health's Connection
Additionally, it's important to note the potential implications for Evolent Health (NYSE: EVH), a key player that contributes significantly—about 21.8%—to Evolent's revenue. The updates from Humana are likely to resonate within Evolent’s operations, but JPMorgan remains optimistic with its Overweight rating and a $45.00 price target for Evolent Health, highlighting that the fees for managing specialty care within Medicare Advantage contracts remain unaffected.
Insights from InvestingPro
In response to Humana's recent challenges, data from InvestingPro provides further insights for investors. Although there could be implications on future premiums due to the star rating changes, Humana has exhibited strong financial metrics. As of Q2 2024, the company's revenue reached an impressive $112.04 billion, alongside a healthy revenue growth rate of 13.48% for the same period.
Commitment to Shareholder Returns
InvestingPro Tips reveal that Humana has sustained dividend payments for 14 consecutive years, with a commendable increase in dividends for the past 7 years. This commitment to rewarding shareholders could offer reassurance to those troubled by the potential financial effects of the star rating adjustments.
Stock Performance and Investor Considerations
Humana's stock performance has been responsive to the recent news regarding the star rating decline, noted by a 20.95% decrease over the past month. Nonetheless, with its P/E ratio standing at 17.41 and a price-to-book ratio of 2.02, the company may present attractive valuation opportunities for long-term investors who trust in Humana’s ability to navigate its current challenges successfully.
Frequently Asked Questions
What is the current star rating for Humana's plans?
Humana's recent disclosure revealed that only 25% of its members will be enrolled in plans rated 4 stars or above for 2025.
How has TD Cowen rated Humana recently?
TD Cowen has maintained a Buy rating on Humana, sustaining a price target of $402.00 despite the recent rating challenges.
What financial impacts are expected due to the rating drop?
The decrease in star ratings could significantly affect Humana's premiums in 2026 and impact the company's earnings per share and profit margins.
Which companies have retained ratings on Humana?
Barclays has maintained an Overweight rating, while Morgan Stanley and JPMorgan have kept their Neutral ratings. However, Leerink Partners downgraded Humana from Outperform to Market Perform.
How has Humana performed financially in recent times?
Humana reported a revenue of $112.04 billion for the last twelve months as of Q2 2024, indicating a revenue growth of 13.48% during that period.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Celebrating Community: Canadian REALTORS Care® Award 2025
- Spero Therapeutics Unveils Positive Results for SPR720 Drug Trials
- Know Labs Faces Compliance Challenges with NYSE American
- Humana Faces Challenges as BofA Downgrades Outlook
- Positive Trends in Brazilian Stocks as Bovespa Closes Higher
- Vascular Biogenc Faces Challenges as NTBL Stock Hits Low
- Celebrating Hispanic Business Success Through SBA Support
- Celsius Holdings Faces Market Challenges as Stock Prices Decline
- Cemtrex Inc. Faces Major Challenges as CETX Stock Hits Low
- BioLineRx Faces Market Challenges as Stock Plummets
Recent Articles
- TransMedics Group: A Bright Future with Record Growth Ahead
- Investors Alert: Class Action Filed Against Nano Nuclear Energy
- SAIC's Pipeline Growth and Booz Allen Valuation Insights
- HII Launches Cutting-Edge Lab to Enhance Space Coatings
- XPEL, Inc. Under Legal Scrutiny - Shareholder Insights
- Qylur's Innovative AI Spectrum Classifier Secures Funding Boost
- Alkimi Elevates Its Strategy with New Executive Appointment
- Exploring the Recent Surge in Caesars Entertainment Stock
- Elon Musk's Dogecoin Journey: From McDonald's to Government Efficiency
- Investing $1000 in Expedia Group: A Compounding Success Story
- Hess Corporation Sets Date for Third Quarter Earnings Release
- Investing $1000 in Novavax: A 5-Year Journey to Wealth
- Job Growth Trends and Potential Fed Rate Cuts Unraveled
- Market Insights: Stocks Slightly Up Despite ConAgra's Woes
- Hyland's Strategic Appointment of Steve Baird as CRO
- Experience the Magic of Día de los Muertos Celebration
- Katten's Lance Zinman Joins MFA Board of Directors
- UST Expands Influence in Automation with ISG Acquisition
- BullBag® Boosts Support for Hurricane Recovery Efforts
- Granite REIT Announces Strategic C$800 Million Debenture Offering
- Lexaria Bioscience Welcomes New CFO Michael Shankman
- Michael C. Burgess Executes Sale of Illumina Stocks Raising Eyebrows
- JPMorgan Projects Strong Future for NVIDIA with $155 Price Target
- Deutsche Bank Affirms Joby Aviation Sell Rating Amid Challenges
- Changes in Leadership at T Stamp Inc.: What to Know
- Tecnoglass Inc. (TGLS) Reaches New Heights with Stock Surge
- Understanding Financial Impacts on Bank Millennium’s Performance
- Exploring the Future Growth of Tandem Diabetes Care's Innovations
- Impending Beer Shortages: How Port Strikes Affect Imports
- Investigation Launched into Light & Wonder, Inc. by Law Experts
- Understanding the Risks of Investing in Chinese Markets
- Kraft Heinz Company: Adapting Pricing Strategies for Future Growth
- Investors of Allarity Therapeutics, Inc. Can Take Action Now
- Wilson Elser Achieves Mansfield Certification Plus for 2023-2024
- Avocados From Mexico Recognized as a Great Place to Work
- How Current Oil Supply Dynamics Affect Market Stability
- Chris Miller Honored as New VP of Total Rewards at Firm
- Magma Power Achieves Patent for Revolutionary Hydrogen Technology
- Tesla Eyes Future Growth Amidst Recent Delivery Challenges
- Humana Achieves Stability Amid Changes in Star Ratings
- Cumulus Media Faces Challenges as Shares Hit Record Low
- ORIX Corporation Enhances Employee Incentives with Share Disposal
- Mesa Laboratories Declares Quarterly Dividend Amid Positive Growth
- A-Mark Precious Metals Enhances Credit Agreement Through 2026
- Goldman Sachs Predicts Mortgage Rates to Stabilize at 6% in 2024
- Upcoming Earnings Reports: Constellation, AngioDynamics, Tesco
- Key Economic Reports to Influence Markets This Thursday
- Innovative Solutions by Gilbarco Veeder-Root Emphasizing Sustainability
- Invenco by GVR Unveils Innovative Solutions for Retail Enhancement
- Revolutionizing Bitcoin Mining with GDMining's Latest System